90818040
Jul 8, 2021
Proteins being recombinant proteins in the nature of pharmaceutical preparations and substances for the treatment of autoimmune, allergic and inflammatory diseases and disorders; Proteins being recombinant proteins in the nature of pharmaceutical preparations and substances for the treatment of autoimmune, allergic and inflammatory diseases by eliminating specific lymphocytes lineages or modulating the immune response using a variety of recombinant proteins; Pharmaceutical preparations and substances for the treatment of autoimmune, allergic and inflammatory diseases and disorders by modulating the immune system by recombinant proteins that contain a targeting moiety and an effector moiety to eliminate specific lymphocytes lineages and attenuate or block the antibody creation and antigen specific immune response in autoimmune, Allergic and inflammatory diseases; Pharmaceutical preparations and substances for the treatment of autoimmune, allergic and inflammatory diseases and disorders by modulating the immune system by recombinant proteins that contain a targeting moiety and an effector moiety to eliminate specific lymphocytes lineages and attenuate or block the creation of the antibodies IgG, IgE or IgA and antigen specific immune response in autoimmune, allergic and inflammatory diseases; Proteins including recombinant proteins pharmaceutical preparations and substances with potential immunomodulation activity to treat under and over responsiveness of the immune system
Pharmaceuticals